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CC BY-NC-ND license (http://creativeBackground/purpose: Patients with serum antigastric parietal cell antibody (GPCA) positivity
may have vitamin B12 deficiency and some oral symptoms. This study assessed the changes
of serum GPCA titer in GPCA-positive patients after effective vitamin B12 treatment.
Methods: Two hundred and ten GPCA-positive oral mucosal disease patients became oral
symptom free (complete response) after 1.0e67.1 months of treatment with regular and
continuous intramuscular injection of vitamin B12 once per week. The changes of serum GPCA
titers after treatment were evaluated in these 210 patients.
Results: We found a significant drop of the GPCA positive rate from 100% to 42.9% in our 210
complete response patients after effective vitamin B12 treatment (p < 0.001). When 210 pa-
tients were further divided into seven subgroups according to the low to high serum GPCA ti-
ters, we noted that the higher serum GPCA titers decreased to significantly lower levels after
treatment in all seven subgroups (all p < 0.001). However, serum GPCA titers increased to
significantly higher levels in 46 GPCA-positive control patients receiving only oral administra-
tion of two vitamin BC capsules (containing 10 mg of vitamin B12) plus deficient hematinic sup-
plements per day after a follow-up period of 2.7e27 months. A maintenance vitamin B12
treatment once a month could retain the GPCA-negative status in 87% of treated-to GPCA-
negative patients compared with those (10%) without further maintenance vitamin B12 treat-
ment.
Conclusion: Regular and continuous effective vitamin B12 treatment can reduce the relatively
higher serum GPCA titers to significantly lower or undetectable levels in GPCA-positive pa-
tients.ave no conflicts of interest relevant to this article.
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Patients with serum antigastric parietal cell antibody
(GPCA) positivity may have vitamin B12 deficiency, which in
turn causes some oral symptoms.1 Etiologies of vitamin B12
deficiency include inadequate intake, food-bound vitamin
B12 malabsorption, a lack of intrinsic factor or parietal
cells, ileal malabsorption, biological competition (including
bacterial overgrowth and tapeworm infestation), and
transcobalamin II deficiency.2 The intrinsic factor, which is
produced by the parietal cells of the stomach lining, can
avidly bind dietary vitamin B12. The vitamin B12eintrinsic
factor complex is carried to the terminal ileum, where it is
absorbed after binding to intrinsic factor receptors on the
luminal membranes of ileal cells.1e4 In the case of perni-
cious anemia (PA), two mechanisms cause the intrinsic
factor deficiency or inactivation. First, about 85% of PA
patients possess the GPCA that induce destruction of pari-
etal cells and in turn result in failure of intrinsic factor
production.5,6 Second, 40e80% of PA patients have anti-
intrinsic factor antibodies that bind to the vitamin B12-
binding site of the intrinsic factor and subsequently inac-
tivate the vitamin B12 absorption-aiding function of the
intrinsic factor.7,8
Patients with serum GPCA positivity are supposed to
have vitamin B12 deficiency that finally leads to PA.1e6
However, our previous study showed that only 12.9% of
124 GPCA-positive oral mucosal disease patients have PA,
according to the World Health Organization definition.1 In
addition, 16.1%, 20.2%, 16.1%, and 4.0% of 124 GPCA-
positive oral mucosal disease patients have deficiencies of
hemoglobin, iron, vitamin B12, and folic acid, respectively.
Moreover, 32.2% and 30.6% of 124 GPCA-positive patients
also have antithyroglobulin autoantibody (TGA) and anti-
thyroid microsomal autoantibody (TMA, also known as
antithyroid peroxidase antibody) in their sera, respectively.
Furthermore, burning sensation of oral mucosa, dry mouth,
atrophic glossitis (AG), numbness of tongue, and dysfunc-
tion of taste are found in 98.4%, 79.8%, 60.5%, 55.6%, and
24.2% of 124 GPCA-positive patients, respectively.1 As
GPCA-positive patients are prone to have hematinic de-
ficiencies, TGA and/or TMA positivities, and oral symptoms
and signs, these patients are usually treated with intra-
muscular injections of vitamin B12 combined with deficient
hematinic supplement therapy to reduce the oral symptoms
and signs.9e11
In this study, 260 GPCA-positive patients collected from
our oral mucosal disease clinic were treated with regular
and continuous intramuscular injection of vitamin B12 once
a week. Complete remission of all oral symptoms (the so-
called complete response) was found in 210 of the 260
GPCA-positive patients after treatment with intramuscular
injection of vitamin B12 once a week. The serum GPCA ti-
ters of these 210 complete response patients were analyzedto see whether regular and continuous treatment with
intramuscular injection of vitamin B12 once a week plus
deficient hematinic supplement therapy could reduce the
relatively higher serum GPCA titers to significantly lower or
undetectable levels in our 210 GPCA-positive patients. In
addition, we also assessed whether the treated-to GPCA-
negative patients with or without a maintenance treatment
of intramuscular injection of vitamin B12 once a month
could retain the GPCA-negative status in their sera.Materials and methods
Patients and blood samples
The flowchart of patient selection is shown in Figure 1. In
the study period from July 2007 to July 2015, 981 AG and
820 burning mouth syndrome (BMS) patients were seen
consecutively, diagnosed, and treated in the oral mucosal
disease clinic of Department of Dentistry, National Taiwan
University Hospital. We found 345 (236 AG and 109 BMS)
patients to be serum GPCA positive. Of these 345 GPCA-
positive patients, 39 receiving irregular and intermittent
treatment were excluded from this study, and 260 received
regular and continuous treatment with intramuscular in-
jection of vitamin B12 once a week plus oral vitamin BC
treatment and deficient hematinic supplement therapy. Of
these 260 regularly treated GPCA-positive patients, 210
showed complete remission of all oral symptoms and were
designated as the complete response group, and the
remaining 50 who exhibited partial remission of oral
symptoms were designated as the partial response group
and further excluded from this study. Moreover, 46 GPCA-
positive patients who refused intramuscular injection of
vitamin B12 once a week but received regular and contin-
uous oral vitamin BC treatment and deficient hematinic
supplement therapy were designated as the control group.
This study aimed to analyze the changes of serum GPCA,
TGA, and TMA titers at baseline and after treatment in
these 210 complete response patients (including 151 AG and
59 BMS patients, 41 men and 169 women, age range
22e92 years, mean age 61.4  12.6 years). Furthermore,
the serum GPCA titers of 46 control patients (including 37
AG and 9 BMS patients, 6 men and 40 women, age range
34e86 years, mean age 62.4  12.1 years) were evaluated
to see whether the relatively higher serum GPCA titers
could be reduced after oral vitamin BC treatment and
deficient hematinic supplement therapy only.
In this study, patients were diagnosed as having partial
or complete AG when their dorsal tongues showed partial or
complete absence or flattening of filiform papillae,
respectively. Moreover, patients with burning sensations of
the oral cavity in the absence of physical abnormalities of
the oral mucosa were diagnosed to have BMS. This study
Figure 1 Flowchart of patient selection. AG Z atrophic glossitis; BMS Z burning mouth syndrome; GPCA Z antigastric parietal
cell antibody.
Vitamin B12 treatment reduces GPCA titer 839adopted a loose definition for BMS, and thus both primary
and secondary BMS patients were included in this
study.9,12,13 None of our control and complete response
patients had autoimmune diseases (such as systemic lupus
erythematosus, rheumatoid arthritis, Sjogren’s syndrome,
pemphigus vulgaris, and cicatricial pemphigoid). Moreover,
none of them had taken any prescription medication for AG
or BMS at least 3 months before entering the study.For these 210 complete response patients, oral symp-
toms (such as burning sensation of oral mucosa, dry mouth,
numbness of the tongue, and loss or dysfunction of taste)
were inquired and recorded. Blood samples were drawn
from 210 complete response patients at baseline, after
treatment till complete response, and during the follow-up
period for the measurement of serum GPCA, TGA, and TMA
titers. In addition, blood samples were also drawn from 46
840 A. Sun et al.control patients at baseline and during the follow-up
period. This study was reviewed and approved by the
Institutional Review Board of the National Taiwan Univer-
sity Hospital.
Treatment of GPCA-positive patients with vitamin
B12 and other deficient hematinics
In this study, 260 GPCA-positive patients were treated with
regular and continuous intramuscular injections of vitamin
B12 (1 ampule/wk; each ampule contained 1000 mg of
hydroxocobalamin in 1 mL of distilled water) and oral
administration of vitamin BC capsules (1 capsule, twice a
day; each capsule contained 10 mg of vitamin B1, 5 mg of
vitamin B2, 5 mg of vitamin B6, 5 mg of vitamin B12, 20 mg
of calcium pantothenate, 50 mg of nicotinamide, 150 mg of
vitamin C, and 60 mg of calcium). The 260 GPCA-positive
patients with concomitant folic acid deficiency (folic
acid  6 ng/mL) or iron deficiency (iron  70 mg/dL for men
and  65 mg/dL for women) received oral administration of
folic acid tablets (2 tablets/d for 2 months and 1 tablet/
d thereafter; each tablet contained 5 mg of folic acid) or
iron tablets [1 tablet/d; each tablet contained 100 mg of Fe
(OH)3 polymaltose complex], respectively. Furthermore,
GPCA-positive patients with dysfunction of taste (n Z 53)
were given additional supplementation of zinc tablets (2
tablets/d; each tablet contained 10 mg of zinc). The first
end point of this study was complete remission of all oral
symptoms including the burning sensation of oral mucosa,
dry mouth, numbness of the tongue, and dysfunction of
taste. After a certain period of abovementioned hematinic
(especially vitamin B12) supplement treatments, 210 GPCA-
positive patients showed complete response and 50 GPCA-
positive patients exhibited partial response (Figure 1).
Moreover, the serum GPCA, TGA, and TMA titers of these
210 complete response patients at baseline, after treat-
ment, and during the follow-up period were analyzed to see
whether regular and continuous treatment with intramus-
cular injection of vitamin B12 once a week (combined with
deficient hematinic supplement treatments in some pa-
tients) could reduce the GPCA, TGA, and TMA titers in their
sera. Furthermore, we also assessed whether oral vitamin
BC treatment and deficient hematinic supplement therapy
only (without an intramuscular injection of vitamin B12)
could reduce the relatively higher serum GPCA titers in 46
control patients. In addition, we also followed up 75 AG or
BMS patients who were originally GPCA positive but became
GPCA-negative after the aforementioned vitamin B12 in-
jections and other hematinic supplement treatments, to
see whether these treated-to GPCA-negative patients with
or without regular and continuous intramuscular injections
of vitamin B12 (1 ampule/mo; each ampule contained
1000 mg of hydroxocobalamin in 1 mL of distilled water)
could retain the GPCA-negative status in their sera.
Determination of serum GPCA level
The serum GPCA level was detected by the indirect
immunofluorescence technique with rat stomach as a sub-
strate, as described previously.1,11,14,15 In brief, 5 mm-thick
cryostat sections of substrate tissues on slides were reactedwith serially diluted patients’ sera in a moist chamber at
room temperature for 30 minutes. The initial dilution of the
patients’ sera was 1:10 with phosphate-buffered saline
(PBS). After washing, the sections were incubated with
fluorescein isothiocyanate-labeled goat antihuman IgG
antiserum (Boehringer Mannheim Biochemicals, Indian-
apolis, IN, USA), which had been prediluted and kept in a
dropper vial by the manufacturer and was ready to use for
another 30 minutes. The sections were washed again,
mounted with buffered glycerin, and examined using an
Olympus fluorescence microscope (Olympus, Tokyo,
Japan). Sera were scored as positive when they produced
fluorescence at a dilution of 10-fold or more.
Determination of serum antithyroglobulin or
antithyroid microsomal antibody level
TGA and TMA titers were measured by a semiquantitative
microtiter particle agglutination test using Serodia-AMC kits
(Fujirebio Inc., Tokyo, Japan), as described previously.14,15
In brief, serial twofold dilutions of initial 1:20 dilutions of
GPCA-positive patients’ sera in the wells of a microtitration
tray were reacted with gelatin particles sensitized with
thyroglobulin or thyroid microsomal antigen at room tem-
perature for 3 hours. The results were obtained by reading
the settling patterns of the colored gelatin particles using a
tray viewer. Serum containing TGA or TMA reacted with the
thyroglobulin or thyroid microsomal antigen-sensitized
colored gelatin particles to form a smooth mat of aggluti-
nated particles in the microtitration tray. Negative re-
actions were characterized by a compact button formed by
the settling of the nonagglutinated particles. TGA or TMA
titers equal to or greater than 1:40 were considered
positive.
Statistical analysis
Comparisons of the frequencies of presence of each oral
symptom and autoantibody positive rates between patients
at baseline and those after treatment till complete
response were performed by chi-square test. Comparison of
serum GPCA titers between complete response or control
patients at baseline and after treatment was performed by
paired t test. Moreover, the recurrence rates of serum
GPCA positivity between 55 treated-to GPCA-negative pa-
tients with a maintenance treatment of vitamin B12 once a
month and 20 treated-to GPCA-negative patients without
further treatment of vitamin B12 were also compared by
chi-square test. The result was considered to be significant
for p < 0.05.
Results
At baseline, burning sensation of oral mucosa, dry mouth,
numbness of the tongue, and dysfunction of taste were
noted in 208 (99.0%), 139 (66.2%), 86 (41.0%), and 53
(25.2%) of 210 GPCA-positive patients, respectively. Com-
plete response was found after regular and continuous
treatment with intramuscular injections of vitamin B12
(combined with deficient hematinic supplement therapy in
Table 2 GPCA-, TGA-, and TMA-positive rates of 210
GPCA-positive complete response patients at baseline and
after treatment mainly with intramuscular injection of
vitamin B12 once a week (combined with deficient hema-




GPCA-positive patients (n Z 210)
Patient number (%)
pa




GPCA positivity 210 (100.0) 90 (42.9) <0.001
TGA positivity 49 (23.3) 44 (21.0) 0.638
TMA positivity 58 (27.6) 55 (26.2) 0.826
GPCA Z antigastric parietal cell antibody;
TGA Z antithyroglobulin antibody; TMA Z antithyroid micro-
somal antibody.
a Comparisons of autoantibody positive rates between pa-
tients at baseline and after treatment until complete remission
of all oral symptoms by chi-square test.
Vitamin B12 treatment reduces GPCA titer 841some patients) for 1.0e67.1 months in these 210 GPCA-
positive patients (Table 1).
The serum GPCA, TGA, and TMA titers were monitored in
these 210 complete response patients at baseline and after
treatment. We found a significant drop of the GPCA positive
rate from 100% to 42.9% in these 210 complete response
patients (p < 0.001) (Table 2). There was also a slight
decrease of the TGA positive rate from 23.3% to 21.0%, and
of the TMA positive rate from 27.6% to 26.2%, but the dif-
ferences were not significant (Table 2).
When 210 complete response GPCA-positive patients
were further divided into 151 AG patients and 59 BMS pa-
tients, we found that serum GPCA titers fell from
122.9 13.1 to 31.6 5.4 (p< 0.001) in 151 AG patients, and
from 178.8  29.8 to 55.6  12.8 (p < 0.001) in 59 BMS pa-
tients (Table 3). Moreover, when 210 complete response
GPCA-positive patients were further divided into seven
subgroups according to the low (10-fold dilution of serum) to
high (640-fold dilution of serum) serum GPCA titers, we also
noted that the relatively higher serum GPCA titers could
reduce to different significantly lower levels in all seven
subgroups of patients (all p < 0.001) after the main treat-
ment of intramuscular injection of vitamin B12 once a week
for 1.0e67.1months.We also found that patientswith higher
GPCA titers needed longer periods of vitamin B12 injection
treatment to achieve complete response (Table 3).
The changes of serum GPCA titers in 46 control patients
after oral vitamin BC treatment and deficient hematinic
supplement therapy only are shown in Table 4. In 37 AG
patients, we found a significant increase in the serum GPCA
titer from 186.2  33.4 to 397.3  58.2 after a mean of
9.4  6.5 months of treatment with only oral administration
of vitamin BC capsules and other deficient hematinic sup-
plements. Moreover, in nine BMS patients, a significantTable 1 Oral symptoms of the 210 GPCA-positive patients
at baseline and after treatment mainly with intramuscular
injection of vitamin B12 once a week (combined with defi-
cient hematinic supplement therapy in some patients) for
1.0e67.1 months until complete remission of all oral
symptoms.










208 (99.0) 0 (0) <0.001
Dry mouth 139 (66.2) 0 (0) <0.001
Numbness of
tongue
86 (41.0) 0 (0) <0.001
Dysfunction of
taste
53 (25.2) 0 (0) <0.001
GPCA Z antigastric parietal cell antibody.
a Comparison of the frequencies of presence of each oral
symptom between patients at baseline and after treatment
until complete remission of all oral symptoms by chi-square
test.elevation in serum GPCA titer from 266.7  94.9 to
555.1  151.1 was discovered after a mean of
14.3  7.8 months of treatment with only oral administra-
tion of vitamin BC capsules and other deficient hematinic
supplements. When the 46 control patients were further
divided into seven subgroups according to the low to high
serum GPCA titers, we also noted increases of serum GPCA
titers in all the seven subgroups, although a significant in-
crease of serum GPCA titer was found in only three sub-
groups with a patient number of eight or more (Table 4).
Follow-up data were available for analyses for 75 AG or
BMS patients who were originally GPCA positive but
became GPCA negative after treatment with regular and
continuous intramuscular injection of vitamin B12 once a
week. After a follow-up period of 3.0e48.5 months (mean
13.3  10.1 months), we found that a maintenance treat-
ment of intramuscular injection of vitamin B12 once a
month could retain the GPCA-negative status in 87% of
treated-to GPCA-negative patients compared with those
(10%) without further maintenance vitamin B12 treatment
(Table 5).Discussion
Patients with GPCA positivity are prone to have destruction
of gastric parietal cells by an autoimmune mechanism,
resulting in deficiency of intrinsic factor, a lack of absorp-
tion of vitamin B12 from small intestine, vitamin B12 defi-
ciency, and finally PA.2 Patients with a variety of hematinic
(including vitamin B12) deficiencies or different types of
hematinic-deficient anemia are prone to have oral symp-
toms such as burning sensation of oral mucosa, dry mouth,
numbness of the tongue, and dysfunction of
taste.3,9,10,13,16e22 In this study, 260 GPCA-positive oral
mucosal disease patients were treated with regular and
continuous intramuscular injections of vitamin B12 com-
bined with deficient hematinic supplement therapy for
Table 3 Serum titers of GPCA in 151 AG and 59 BMS patients before and after treatment mainly with intramuscular injection of
vitamin B12 once a week until complete remission of all oral symptoms.
Main treatment
modalitya
Patient type or GPCA titer Duration of treatment
until complete
remission of all oral
symptoms (mo)
Serum titers of GPCA (fold of dilution
of serum)
pb
Range Mean  SD At baseline After treatment till
complete remission
of all oral symptoms
Mean  SEM Mean  SEM
Vitamin B12 AG (n Z 151) 1.0e67.1 15.5  13.4 122.9  13.1 31.6  5.4 <0.001
Vitamin B12 BMS (n Z 59) 2.0e50.0 15.3  13.1 178.8  29.8 55.6  12.8 <0.001
Vitamin B12 GPCA titer Z 10 (n Z 15) 2.1e6.8 3.7  1.6 10 0.0  0.0 <0.001
Vitamin B12 GPCA titer Z 20 (n Z 55) 1.0e22.1 6.3  4.2 20 0.6  0.3 <0.001
Vitamin B12 GPCA titer Z 40 (n Z 37) 2.8e41.0 14.9  9.8 40 6.5  1.4 <0.001
Vitamin B12 GPCA titer Z 80 (n Z 38) 3.7e39.4 16.9  11.1 80 10.5  2.2 <0.001
Vitamin B12 GPCA titer Z 160 (n Z 23) 3.0e52.2 22.4  17.5 160 37.4  6.8 <0.001
Vitamin B12 GPCA titer Z 320 (n Z 23) 7.4e67.1 25.0  14.7 320 81.7  10.2 <0.001
Vitamin B12 GPCA titer Z 640 (n Z 19) 8.0e51.3 29.8  12.2 640 240.0  22.9 <0.001
AG Z atrophic glossitis; BMS Z burning mouth syndrome; GPCA Z antigastric parietal cell antibody; SD Z standard deviation;
SEM Z standard error of the mean.
a GPCA-positive patients were treated mainly with intramuscular injection of vitamin B12 once a week (combined with deficient
hematinic supplement treatments in some patients).
b Comparison of serum GPCA titers between patients at baseline and after treatment until complete remission of all oral symptoms by
paired t test.
Table 4 Serum titers of GPCA in 37 AG and nine BMS control patients before and after oral vitamin BC treatment and deficient
hematinic supplement therapy only (without intramuscular injection of vitamin B12).
Patient type or GPCA titer Duration of treatment (mo) Serum GPCA titer (fold of dilution of serum) p





Mean  SEM Mean  SEM
AG (n Z 37) 2.7e29.0 9.4  6.5 186.2  33.4 397.3  58.2 <0.001a
BMS (n Z 9) 4.1e27.0 14.3  7.8 266.7  94.9 555.1  151.1 <0.001a
GPCA titer Z 10 (n Z 3) 3.7e8.0 5.2  2.4 10 33.3  6.7 0.073
GPCA titer Z 20 (n Z 7) 2.7e24.7 8.8  8.1 20 114.3  41.1 0.062
GPCA titer Z 40 (n Z 4) 3.4e6.1 4.5  1.2 40 130.0  30.0 0.058
GPCA titer Z 80 (n Z 8) 3.6e13.3 7.7  2.9 80 300.0  76.7 0.024a
GPCA titer Z 160 (n Z 12) 2.8e29.0 11.6  6.9 160 440.0  52.6 <0.001a
GPCA titer Z 320 (n Z 4) 5.6e25.2 15.7  8.7 320 560.0  80.0 0.058
GPCA titer Z 640 (n Z 8) 3.3e27.0 14.6  7.4 640 1040.0  117.1 0.011a
AG Z atrophic glossitis; BMS Z burning mouth syndrome; GPCA Z antigastric parietal cell antibody; SD Z standard deviation;
SEM Z standard error of the mean.
a Comparison of serum GPCA titers between patients at baseline and after treatment by paired t test with p < 0.05.
842 A. Sun et al.some patients. We found that 210 GPCA-positive patients
showed complete remission of all oral symptoms (complete
response) after treatment for 1.0e67.1 months depending
on the initial serum titer of GPCA and hematinic (espe-
cially, vitamin B12) deficiencies. Statistical analyses
demonstrated that GPCA positive rate of the 210 complete
response patients could be significantly reduced from 100%to 42.9%, but the patients’ TGA and TMA positive rates were
only slightly reduced from 23.3% to 21.0% and from 27.6% to
26.2%, respectively. When the GPCA-positive oral mucosal
disease patients were further divided into AG or BMS sub-
groups or into seven subgroups according to the low to high
GPCA titers, the relatively higher GPCA titers of the 210
complete response patients could be reduced to
Table 5 Follow-up data of 75 oral mucosal disease patients who were originally GPCA positive but became GPCA negative
after treatment with regular and continuous intramuscular injection of vitamin B12 (1000 mg of hydroxocobalamin, once a
month).
Group Patient number (%) p (Chi-square test)
Recurrence of GPCA in sera No recurrence
55 treated-to GPCA-negative patients
with a maintenance treatment of
vitamin B12 once a month
7 (13%) 48 (87%) <0.001
20 treated-to GPCA-negative patients
without further treatment of vitamin B12
18 (90%) 2 (10%)
Of the 75 treated-to GPCA-negative patients, 55 underwent a maintenance treatment of regular and continuous intramuscular injection
of vitamin B12 once a month and 20 received no further treatment of vitamin B12. These 75 treated-to GPCA-negative patients were
followed up for a period of 3.0e48.5 months (mean, 13.3  10.1 months).
GPCA Z antigastric parietal cell antibody.
Vitamin B12 treatment reduces GPCA titer 843significantly lower or undetectable levels in all the nine
subgroups of GPCA-positive patients (all p < 0.001). It was
also interesting to find a significant elevation of serum
GPCA titer in 37 AG and nine BMS control patients who
refused to receive intramuscular injections of vitamin B12
but received oral vitamin BC treatment plus deficient he-
matinic supplement therapy after a mean follow-up period
of 9.4 months and 14.3 months, respectively. Moreover,
oral administration of two vitamin BC capsules (containing
10 mg of vitamin B12) per day and other deficient hematinic
supplement therapies were not enough to reduce the
relatively higher serum GPCA titer to a lower level in our
control patients without intramuscular injection of vitamin
B12 once a week in the follow-up period. Finally, we
observed that 87% of treated-to GPCA-negative patients
receiving a regular and continuous maintenance vitamin
B12 treatment once a month could retain the GPCA-
negative status in their sera. In contrast, only 10% of
treated-to GPCA-negative patients could retain the GPCA-
negative status in their sera when they stopped to receive
the further maintenance treatment of vitamin B12 once a
month. The above findings indicate that only effective
vitamin B12 supplement therapy is sufficient to lower the
serum GPCA titer and maintain the GPCA-negative status in
patients’ sera for a long period.
It was still not clear why regular and continuous vitamin
B12 treatment could reduce the patients’ GPCA titers from
a relatively higher level to a significantly lower or unde-
tectable level, and why the serum GPCA-negative status in
the majority of treated-to GPCA-negative patients returned
to a serum GPCA-positive status when they did not receive
further maintenance vitamin B12 treatment once a month.
GPCA-positive patients usually have destruction of gastric
parietal cells by an autoimmune mechanism.1 However, it
may need a sufficiently long period of time to develop into
very severe autoimmune gastritis in GPCA-positive patients.
When GPCA-positive patients have only mild or moderate
autoimmune gastritis, these patients may still have some
parietal cells retained in their gastric mucosae. Continuous
destruction of the remaining gastric parietal cells may
release more gastric parietal cell antigens into the local
tissues. A portion of these released gastric parietal cell
antigens diffuse into lymphatic vessels, which are, in turn,
carried to regional lymph nodes. These released gastricparietal cell antigens are subsequently phagocytized by the
histiocytes or B cells in the local gastric tissues and regional
lymph nodes, and they are further processed and presented
to helper T cells. GPCA-producing plasma cells are thus
formed through the assistance of helper T cells and begin to
secrete GPCA into the local gastric tissues and regional
lymph nodes. Finally, parts of the secreted GPCAs are
collected into the blood stream. Those GPCA-positive pa-
tients who are in the gastric parietal cell destruction stage
may fall into a vicious cycle with the production of more
GPCAs in their local gastric tissues, regional lymph nodes,
and blood streams. This can explain why our GPCA-positive
patients in different developmental stages of the autoim-
mune gastritis may have different GPCA titers in their sera.
Regular and continuous effective vitamin B12 therapy may
reverse the severe autoimmune gastritis to moderate or
mild gastritis or even to a nearly normal gastric mucosa
status. This can further explain why our GPCA-positive pa-
tients with different severities of autoimmune gastritis may
reduce their relatively higher serum GPCA titers to signifi-
cantly lower or undetectable levels after effective vitamin
B12 therapy. Our previous study also found that treatment
modality containing intramuscular injections of vitamin B12
can effectively reduce the high serum GPCA level to an
undetectable level in GPCA-positive oral lichen planus pa-
tients.11 However, patients with an undetectable level of
GPCA titer mean that they may still have little but unde-
tectable GPCAs in their sera. Thus, they need a mainte-
nance vitamin B12 treatment to keep the serum GPCA titer
undetectable. In case of patients who receive no further
maintenance vitamin B12 treatment, GPCA may be pro-
duced again in bodies through the aforementioned vicious
cycle mechanism, finally resulting in the recurrence of
GPCA positivity in patients’ sera. However, we still have to
keep in mind that having serum GPCA positivity in patients
does not imply that they should have autoimmune
gastritis.2,5 GPCA is generally nonspecific; it is often pre-
sent in patients with autoimmune endocrinopathies and is
also present in 3e10% of healthy individuals, depending on
age.6,23 In this specific group of patients or healthy in-
dividuals, regular and continuous vitamin B12 treatment
may also have some effects on the reduction of relatively
higher serum GPCA titers to significantly lower or unde-
tectable levels.
844 A. Sun et al.As patients with organ-specific autoimmune disease are
prone to have other organ-specific autoantibodies in their
sera,24,25 it was not surprising to find that 23.3% and 27.6%
of our GPCA-positive patients also had TGA and TMA in their
sera. Although patients with serum TGA and/or TMA posi-
tivity do not mean that they should have autoimmune
thyroiditis,24,25 and regular and continuous vitamin B12
treatment is aimed at reversing the autoimmune gastritis
(but not autoimmune thyroiditis) from a severe status to a
less severe status in our GPCA-positive patients, a small
number of our TGA- or TMA-positive patients may become
TGA negative or TMA negative through an unknown mech-
anism after a regular and continuous vitamin B12
treatment.
We conclude that regular and continuous effective
vitamin B12 therapy combined with deficient hematinic
supplement therapy can not only lead to complete remis-
sion of all oral symptoms in our GPCA-positive patients, but
also reduce the relatively higher serum GPCA titers to
significantly lower or undetectable levels in our complete
response GPCA-positive patients. Moreover, patients with
higher GPCA titers may need longer periods of effective
vitamin B12 treatment to achieve complete response. A
regular and continuous maintenance treatment of intra-
muscular injection of vitamin B12 once a month can pre-
vent the transformation of GPCA negativity into GPCA
positivity again. However, if the GPCA-positive patients do
not receive any effective vitamin B12 treatment and other
deficient hematinic supplement therapies (a natural course
of the disease), there is almost no chance to bring the
patients to the GPCA-negative status or render them free
from oral symptoms.
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